CD46 and neoplasm: Given the restricted PVRL4 distribution to most human body tissues compared to the ubiquitous CD46 expression and the presence of SLAM on activated lymphocytes and dendritic cells, PVRL4 is a promising tumor-associated marker for cancer therapy.